窪蹋勛圖厙

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 窪蹋勛圖厙 News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Mar 31 2020

Full Issue

At Dawn Of Opioid Crisis, Johnson & Johnson Genetically Created 'Supper Poppy' That Was Rich In Opiates

The Washington Post takes a look at Johnson & Johnson's operations in Tasmania, which produced genetically modified "supper poppy" plants. In other public health news: e-cigarettes, mental health services, Alzheimer's treatments, and dementia.

Johnson & Johnson, a company more widely known for baby powder and Band-Aids, became a major supplier of narcotic raw materials to the U.S. thanks to a Tasmanian breed of poppies. (Whoriskey, 3/26)

In January 2019, the chairman of Altria, Howard A. Willard III, flew to Silicon Valley to speak to senior executives of Juul Labs, fresh off signing a deal for the tobacco giant to pay nearly $13 billion for a 35 percent stake in the popular e-cigarette company. With public fury growing over Juuls contribution to the epidemic of teenage vaping, he laid out his vision for the company to continue to thrive. I believe that in five years, 50 percent of Juuls revenue will be international, Mr. Willard told the 200 executives gathered at the Four Seasons in East Palo Alto. (Kaplan, Jacobs and Sang-Hun, 3/30)

Georgia Tech, more so than any state school in recent years, has faced public pressure and scrutiny to better help students struggling with such issues. Two students died near the end of the fall 2018 semester from apparent suicides. The family of Scout Schultz, a Georgia Tech student shot and killed by a campus police officer in 2017, filed a wrongful death lawsuit in September against the school. (Stirgus, 3/31)

The fate of aducanumab, a potential Alzheimers treatment from Biogen, is widely seen as the last hope for an aging idea: that targeting toxic brain plaques can arrest the progress of the disease. But theres a similar, less-discussed Alzheimers treatment working through a pivotal trial. And its outcome, positive or negative, could shift the yearslong debate over how best to target Alzheimers. (Garde, Robbins and Feuerstein, 3/30)

In summer 2014, when he was 54, Sacramento artist David Wetzl was exhibiting the behaviors of an elderly man with Alzheimers. I have a bad brain, he told everyone repeatedly, using a simple phrase to explain his diagnosis to the world. Two years before that, his wife, Diana Daniels, had asked for an MRI because she was suspicious that things werent right and fearful when he couldnt remember the word shoelaces. The scan showed with horrific clarity how sections of his brain had shriveled. (Mailman, 3/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 窪蹋勛圖厙
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

穢 2026 KFF